Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Karl D. Lewis | Researchclopedia

Back to researchers

Karl D. Lewis

Regeneron (United States)ORCID

349

Works

28,135

Citations

62

h-index

145

i10-index

Research Topics

Cancer Immunotherapy and Biomarkers Melanoma and MAPK Pathways CAR-T cell therapy research

Affiliations

AstraZeneca (United Kingdom)2010–2010

University of Southern California2010–2010

Norwalk Hospital2008–2008

Cedars-Sinai Medical Center2010–2010

Translational Genomics Research Institute2013–2013

Top Works

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty,J. Infante,et al.

20122,786 citations

Immunotherapy and Immune Responses

Cutaneous Melanoma Detection and Management

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka,Howard L. Kaufman,et al.

20152,543 citations

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

Jeffrey A. Sosman,Kevin B. Kim,et al.

20122,142 citations

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas,Igor Puzanov,et al.

20151,554 citations

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

Aleksandar Sekulić,Michael R. Migden,et al.

20121,421 citations

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Michael R. Migden,Danny Rischin,et al.

20181,363 citations

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Hussein A. Tawbi,Peter Forsyth,et al.

20181,299 citations

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Howard L. Kaufman,Jeffery S. Russell,et al.

20161,207 citations

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Ralf Gutzmer,Daniil Stroyakovskiy,et al.

2020640 citations